Grand Challenges in Reproductive Endocrinology by Claus Yding Andersen
February 2017 | Volume 7 | Article 1691
Specialty Grand challenGe
published: 08 February 2017
doi: 10.3389/fendo.2016.00169
Frontiers in Endocrinology | www.frontiersin.org
Edited and Reviewed by: 
Jeff M. P. Holly, 
University of Bristol, UK
*Correspondence:
Claus Yding Andersen  
yding@rh.dk
Specialty section: 
This article was submitted to 
Reproduction, a section of the 
journal Frontiers in Endocrinology
Received: 12 September 2016
Accepted: 14 December 2016
Published: 08 February 2017
Citation: 
Andersen CY (2017) Grand 
Challenges in Reproductive 
Endocrinology. 
Front. Endocrinol. 7:169. 
doi: 10.3389/fendo.2016.00169
Grand challenges in reproductive
endocrinology
 
Claus Yding Andersen*
Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children and Reproduction, Copenhagen 
University Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Keywords: reproductive endocrinology, sex steroids, gonadotropins, peptide growth factors, ovary, testes, 
follicles, seminiferous tubles
Reproduction is a fundamental aspect of life in all species. In a biological sense, it can be argued 
that reproduction is the essence of life. Passing on ones genes to the next generation and constantly 
optimizing the gene pool available for each individual and the species as a whole are vital for continu-
ation and endurance of the species. Reproduction and hormones are intimately connected; thus, 
hormones are a prerequisite for reproduction and govern nearly all aspects of successful creation in 
both females and males. Therefore, to numerous scientists, reproductive endocrinology is one of the 
most fascinating disciplines in science, and it is a pleasure that now finally there is a scientific journal 
dedicated specifically to reproductive endocrinology.
Despite the lack of specific journals dedicated entirely to reproductive endocrinology up until 
now, this area has had a huge impact on society with first the development of female oral contracep-
tives around 50 years ago followed by the development of in vitro fertilization techniques to help 
childless couples in 1970–1980s.
Regardless of an enormous amount of literature on sex steroid hormones accumulated over the 
years, there are constantly new aspects of their function in the body and indeed in the reproductive 
organs. One aspect that we will hear more about in the coming years is the aging population, in 
which especially the majority of women will spend up to half of their life in menopause depletion 
of ovarian sex steroids (1). The consequences on general health including osteoporosis and car-
diovascular disease are all aspects within the area of reproductive endocrinology and highlight the 
need for discussing hormone replacement therapy and/or alternative strategies. The male equivalent 
testosterone and the effects of testosterone especially in the aging male is also a matter of debate these 
years, and it is furthermore discussed how to measure testosterone in the clinically most meaningful 
way (2).
Right from the beginning of the IVF era, ovarian stimulation with exogenous FSH preparations 
has been an indispensable component of successful treatment and numerous studies have been con-
ducted to test different compounds and their effect on the reproductive outcome. Although pregnancy 
rates of modern day IVF treatment and ART in general have plateaued during the last decade, the 
journey of optimizing ovarian stimulation is still far from being completed since ongoing pregnancy 
still occurs in only a fraction of treatment cycles. Whereas the follicular phase of the menstrual cycle 
has received intense interest from the very beginning, final maturation of the follicles in connec-
tion with ovulation induction has for many years been performed using a large bolus of hCG as a 
surrogate for the mid-cycle surge of gonadotropins. Recent years have shown that the hCG trigger 
indeed secures maturation of oocytes and stimulates corpora lutea during the first half of the luteal 
phase, but also carries the risk of inducing ovarian hyper stimulation syndrome (OHSS) (3). In order 
to circumvent the risk of OHSS, the agonist trigger was recently introduced, releasing an endogenous 
surge of gonadotropins with much less LH-like activity as compared to the hCG bolus trigger, more 
resembling the natural mid-cycle surge (4). This method can be used in women co-treated with a 
GnRH antagonist. The agonist trigger concept secures final maturation of the pre-ovulatory follicles 
equally well as compared to the hCG trigger, however, it requires additional luteal phase support in 
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order to maintain similar reproductive outcomes (5). The GnRHa 
trigger concept is now gradually replacing the hCG trigger and 
has basically opened the luteal phase for further optimization (6). 
Presently, a number of studies are trying to introduce daily micro-
dose hCG or rec-LH administration as a more appropriate luteal 
phase support than the standard vaginal support. The luteal phase 
support is the last frontier in ovarian stimulation, which needs 
to be carefully scrutinized, and it is still an open field that holds 
the promise of potentially optimizing results further. Importantly, 
the GnRHa trigger has already found its place in general practice 
in connection with patients at risk of OHSS development and in 
oocyte donors (4).
The development of multiple follicles via stimulation with 
exogenous FSH preparations has invariably been accompanied 
with supra-physiological levels of estradiol and progesterone as 
each follicle contributes to the overall concentration observed in 
circulation. Many effects of estradiol in the body are obviously 
reinforced by these high levels, including a risk of inducing a 
pituitary premature LH surge and also negative effects on the 
receptivity of the endometrium. Recent years have shown that 
the endometrium is inappropriately affected by high levels of 
estradiol and the progesterone during the early luteal phase. It 
has, somewhat surprising, now been shown that—if an efficient 
program for freezing oocytes and embryos is available—results 
of a freeze-all strategy with replacement in a subsequent natural 
cycle leads to higher reproductive outcomes, probably due to a 
more appropriate stimulation of the endometrium (7). This has 
raised questions on whether it is possible to reduce the output or 
the effect of estradiol during the follicular phase by for instance 
co-administrating aromatase inhibitors or estrogen receptor 
antagonists to avoid the estrogenic effect on the endometrium.
There is now also a move toward new strategies for ovarian 
stimulation, more in accordance with the gonadotropin actions 
of the natural cycle. One such option is to mimic the natural 
menstrual cycle and use either exogenous LH or hCG for stimula-
tion of follicular growth in the second half of the follicular phase 
until ovulation induction where LH receptors are expressed on 
the granulosa cells and exogenous LH or hCG may substitute for 
exogenous FSH (8–10).
In the vast majority of cases, the pituitary is fully capable of 
producing all the FSH and LH that is required for stimulation of 
multiple follicular development—we need to be able to control its 
release, and a number of new combinations of old and new drugs 
are now becoming interesting and will probably be part of new 
stimulation regimes. It is also of interest to follow the develop-
ment of new hormones for stimulation with a prolonged half-life 
and a pharmacokinetic profile that resembles more the release of 
the hormones in the natural cycle (6).
The apparently ever increasing maternal age of child bearing 
has become an important challenge for many fertility specialists, 
constituting an underlying important task in the management of 
the infertile patient. The development of appropriate hormonal 
tests to determine the biological age in a reproductive context 
and potential ovarian response (e.g., AMH, FSH, and inhibin-
B) receives great attention and has proved clinically valuable. 
However, these tests are likely to be further improved during 
the coming years. Although the ovarian reserve in reproductive 
aged women is most often reduced, the number of resting follicles 
usually constitutes thousands of follicles. Focus is now turning 
toward this huge pool of early stage follicles, which during normal 
circumstances undergo atresia—maybe due to inappropriate 
hormonal stimulation rather than an in built attenuated develop-
mental competence. Attempts to enhance utilization of this pool 
of early stage follicles to augment subsequent mature oocytes 
available for treatment are now under way. Alternatively, it may 
become possible to use part of an increased pool of oocytes to 
augment oocyte quality of other autologous oocytes. More specifi-
cally, we are now starting to understand the hormonal signaling 
pathways that result in initiation of growth in the pool of resting 
primordial follicles, i.e., activation of follicle growth (11–13). A 
new concept to augment the number of mature follicles is now 
being developed in which women with poor ovarian response 
have a biopsy of the ovary, which is subsequently subjected to 
activation of the pool of resting follicles during a short in vitro 
procedure after which the tissue is replaced again. During the 
next months, the pool of activated follicles will grow to the pre-
ovulatory stage. In the best case scenario, more mature follicles 
will result. Ovarian stimulation for the last 2 weeks with exogenous 
hormones is likely to be part of achieving full maturity of these 
follicles. Furthermore, understanding the hormonal regulation of 
follicle growth will be a key feature in developing such concepts 
to a more widespread clinical level, hopefully backed by studies 
in rodents, large domestic species, and primates.
Overall, we are still only starting to understand the regulation 
of follicular growth and indeed how the highly specialized follicu-
lar compartment is hormonally regulated (14). Numerous studies 
have been performed on human follicular fluid from fully mature 
follicles obtained in connection with retrieval of oocytes during 
IVF treatment. This follicular fluid represents, however, the final 
stage of follicular development, in which the follicle and the sur-
rounding theca cells are turning into a corpus luteum that will 
function during the luteal phase. At this time point, the cells are 
undergoing dramatic changes including alterations in gonadotro-
pin receptor expression. Earlier stages of follicular development 
have been studied only to a limited extend, especially because 
human material is very limited for obvious reasons and because 
animal models often present with small sized follicles with a lim-
ited number of cells making detailed studies difficult. However, 
important information will continue to be obtained from animal 
models and especially large domestic species, for instance the 
bovine. A better understanding of the milieu inside small antral 
follicles and their response to hormones derived outside and/or 
inside the follicles is important basic science information, which 
will help optimize conditions for in vitro maturation of oocytes 
and potentially develop new therapeutic approaches that can 
replace the existing IVF procedures. The long-term goal is to be 
able to grow follicles from the earliest stages of development and 
derive mature follicles capable of sustaining fertilization resulting 
in healthy offspring. This has been demonstrated in rodents; how-
ever, a huge research effort is required to take this step in humans.
After the development of the ICSI procedure, endocrinology 
in males received less attention for some years, but new informa-
tion on how to improve sperm function and the hormonal regula-
tion of testicular function is now appearing. It appears that some 
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men with poor sperm quality may benefit from exogenous FSH 
stimulation (15). The importance of specific FSH isoforms and 
genetic variants and FSH receptor polymorphisms (i.e., single 
nucleotide polymorphisms) are being evaluated and a potential 
sensitizing effect of co-administration of LH-like activity (e.g., 
hCG) is another option to potentially improve sperm produc-
tion. The identification of subgroups of patients with a specific 
combination of SNP’s that is more likely to benefit from this 
treatment is a possible scenario that is being tested. The effects 
of testosterone and especially low concentrations of testosterone 
also receives interest and the debate on whether to augment 
concentrations therapeutically is a hot issue—just highlighting 
that more research and information is required to make informed 
decisions.
Studies in animals have been and will continue to be a corner-
stone in understanding reproductive endocrinology. The creation 
of genetically manipulated mice—for instance, mice with a gene 
globally knocked out—and more recently conditional knock out 
models have provided valuable information. However, mice are 
not humans and significant differences exist. Primate or human 
studies are required to confirm the information from animal 
studies. One example is AMH, which in mice appears to attenuate 
follicle recruitment from the resting stage (16). Recent studies 
now suggest that the opposite may be the case in women, where 
two independent studies now have shown that AMH appears to 
stimulate follicular recruitment (17, 18). This may reflect that 
regulation of the biological activity and proteolytic cleavage of 
AMH is complicated; it may differ between sexes and is far from 
being elucidated (19). Later on in folliculogenesis, AMH has a 
number of different functions—one of which is to reduce estra-
diol output by small antral follicles before they become selected 
and chosen to undergo ovulation (20). AMH belongs to the group 
of TGF-β growth factors, which have been shown to undertake 
a huge number of hormonal functions in the gonads. We are far 
from understanding all of the functions of these growth factors, 
their fine tuning, regulation of biological activity, and interplay 
with other hormones. The presence of functional homodimers 
and heterodimers between different members of the TGF-β fam-
ily is new and the functional significance on both the ovary and 
testes remains to be determined (21).
The ability to successfully freeze both human ovarian and 
testicular tissue has allowed development of new treatments to 
preserve fertility by excising and freezing tissue prior to gonado-
toxic treatment often in connection with a cancer disease. The 
transplantation of the tissue to either the remaining ovary or 
outside the ovary creates situations, which have not been seen 
previously. The development of follicles, their hormonal secre-
tion, and the hormonal control of follicular growth provide an 
opportunity to study different conditions that can highlight other 
sides of reproductive endocrinology. The ability to freeze ovar-
ian tissue and the enormous number of resting follicles in the 
ovaries, which to a large extent maintain the capacity to produce 
female sex steroid, has also let to the proposal of more futuristic 
approaches—it is now technically possible to postpone meno-
pause by freezing ovarian tissue during the reproductive years and 
only replace it after menopause (22, 23). Importantly, it will not 
harm the woman—the fertility and the age at menopause do not 
seem to be significantly negatively affected—and the increased 
utilization of the woman’s own follicles will lead to circulating 
levels of estradiol and progesterone, which will effectively prevent 
osteoporosis and cardiovascular disease. However, continued 
menstrual cycling may lead to unwanted side effects such as an 
increased risk of breast cancer, and benefits and drawbacks will 
need to be evaluated carefully in the coming years.
Spermatogonia of intact human testicular tissue are also capa-
ble of surviving freezing and the tissue maintains the capacity to 
secrete specific hormones like AMH and testosterone. However, 
the specific hormonal requirements to culture spermatogonia 
in vitro are not yet in place, and although animal models are not 
similar to the human situation, more information is required 
to understand the physiology better and to potentially reach an 
expertise allowing a clinical approach.
Taken together, reproduction is still a very research intensive 
area with many different disciplines, which calls for a multitude 
of different approaches to obtain a better understanding of 
the physiology of producing new offspring and expand on the 
endocrinology that governs fertility. It is the aim that this new 
initiative—the Reproduction section of Frontiers—will become 
an integrated part of advancing this field in science.
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